EPM’s most read stories of February 2016

With Valentines Day over and Easter fast-approaching, the second month of the year is already drawing to a close. We take a look at our most read stories from the last month. Two down and ten more to go…

Supply chain focus gets medicines to where they are most needed

In this article, guest author, Michael Acott, Baird's CMC, specialist health consultancy, explains how supply chain improvements move medicines more efficiently to poor countries.

To read this story, click here.

AstraZeneca patent expiration forecasts earnings drop

This month EPM covered the news that AstraZeneca’s patent on its anti-cholesterol drug, Crestor, is due to expire in May this year and that with this expiration could come a drop in the company’s profits.

To read this story, click here.

BIOCAPAN Project develops cell therapy product to treat diabetes

This article highlights research by the European Commission funded BIOCAPAN Project which is developing an innovative GMP-grade cell-therapy product to treat diabetes without insulin injections.

To read this story, click here.

Zika: Which came first, the virus or the vaccine?

The Zika virus is spreading rapidly across the Americas with some warning that it will get worse as the weather warms. In this article, EPM’s Emily Hughes takes a look at some of the wild claims surrounding the Zika virus outbreak.

To read this article, click here.

Sanofi to identify Zika vaccine

In this article EPM covers the news that Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.

To read this article, click here.